Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade “A” Success Rate for First-Line Helicobacter pylori Eradication.
This prospective study was to assess the efficacy of nonbismuth containing quadruple therapy as first-line H. pylori treatment and to determine the clinical factors influencing patient outcome. We enrolled 200 H. pylori-infected naïve patients. They were prescribed either a 7-day nonbismuth containi...
| Publicado en: | BioMed Research International Vol. 2015; pp. 1 - 8 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
5/19/2015
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109274331&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 109274331 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 23146133 FT2T jtl: BioMed Research International issn: 23146133 maglogo: N pubinfo: dt: 5/19/2015 vid: 2015 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 109274331 109274331 109274331 10.1155/2015/623732 109274331 ppf: 1 ppct: 7 formats: fmt: @attributes: type: P tig: atl: Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade “A” Success Rate for First-Line Helicobacter pylori Eradication. aug: au: Tai, Wei-Chen Liang, Chih-Ming Lee, Chen-Hsiang Chiu, Chien-Hua Hu, Ming-Luen Lu, Lung-Sheng Kuo, Yuan-Hung Kuo, Chung-Mou Yen, Yi-Hao Kuo, Chung-Huang Chiou, Shue-Shian Wu, Keng-Liang Chiu, Yi-Chun Hu, Tsung-Hui Chuah, Seng-Kee affil: Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta-Pei Road, Niao-Sung District, Kaohsiung City 833, Taiwan sug: subj: Helicobacter Infections Drug Therapy Disease Eradication Esomeprazole Therapeutic Use Amoxicillin Therapeutic Use Metronidazole Therapeutic Use Clarithromycin Therapeutic Use Drug Therapy, Combination Human Esomeprazole Administration and Dosage Amoxicillin Administration and Dosage Metronidazole Administration and Dosage Clarithromycin Administration and Dosage Administration, Oral Confidence Intervals Treatment Duration Prospective Studies Questionnaires Medication Compliance Drug Resistance, Microbial Data Analysis Software Chi Square Test Fisher's Exact Test Univariate Statistics Multivariate Analysis Female Male Middle Age Aged Treatment Outcomes Clarithromycin Adverse Effects Amoxicillin Adverse Effects Metronidazole Adverse Effects Esomeprazole Adverse Effects Pilot Studies Sample Size Taiwan Funding Source Middle Aged: 45-64 years Aged: 65+ years Female Male ab: This prospective study was to assess the efficacy of nonbismuth containing quadruple therapy as first-line H. pylori treatment and to determine the clinical factors influencing patient outcome. We enrolled 200 H. pylori-infected naïve patients. They were prescribed either a 7-day nonbismuth containing quadruple therapy group (EACM, esomeprazole 40 mg twice daily, amoxicillin 1 g twice daily, metronidazole 500 mg twice daily, and clarithromycin 500 mg twice daily) or a 7-day standard triple therapy group (EAC, esomeprazole 40 mg twice daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg twice daily). Follow-up studies to assess treatment responses were carried out 8 weeks later. The eradication rates attained by EACM and EAC groups were 95.6% (95% confidence interval [CI] = 89.4%–98.3%) and 79.3% (95% CI = 70%–86.4%) in the per-protocol analysis (P < 0.001) and 88% (95% CI = 80.2%–93.0%) and 73% (95% I = 63.6%–80.3%) in the intention-to-treat analysis (P = 0.007). Clarithromycin resistance, metronidazole resistance, and dual clarithromycin and metronidazole resistances were the clinical factors influencing H. pylori eradication in EACM group. Clarithromycin resistance and dual clarithromycin and metronidazole resistances were the influential factor for EAC treatment. In conclusion, the results suggest that 7-day nonbismuth containing quadruple therapy could achieve a grade “A” report card for first-line H. pylori treatment. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|